Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.biopha.2021.111363 http://scihub22266oqcxt.onion/10.1016/j.biopha.2021.111363 33582450!7862910!33582450     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biomed+Pharmacother 2021 ; 137 (ä): 111363 Nephropedia Template TP {{tp|p=33582450|t=2021. Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity |pdf=|usr=}}{{33582450}} gab.com Text Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity JO: Biomed Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=33582450 #FOAvip Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of COVID-19, is reported to increase the rate of mortality worldwide. COVID-19 is associated with acute respiratory symptoms as well as blood coagulation in the vessels (thrombosis), heart attack and stroke. Given the requirement of angiotensin converting enzyme 2 (ACE2) receptor for SARS-CoV-2 entry into host cells, here we discuss how the downregulation of ACE2 in the COVID-19 patients and virus-induced shift in ACE2 catalytic equilibrium, change the concentrations of substrates such as angiotensin II, apelin-13, dynorphin-13, and products such as angiotensin (1-7), angiotensin (1-9), apelin-12, dynorphin-12 in the human body. Substrates accumulation ultimately induces inflammation, angiogenesis, thrombosis, neuronal and tissue damage while diminished products lead to the loss of the anti-inflammatory, anti-thrombotic and anti-angiogenic responses. In this review, we focus on the viral-induced imbalance between ACE2 substrates and products which exacerbates the severity of COVID-19. Considering the roadmap, we propose multiple therapeutic strategies aiming to rebalance the products of ACE2 and to ameliorate the symptoms of the disease. Twit Text FOAVip Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity ????Biomed Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=33582450 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33582450 #FOAvip English Wikipedia <ref>{{Cite pmid|33582450}}</ref> Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity #MMPMID33582450 Mehrabadi ME; Hemmati R; Tashakor A; Homaei A; Yousefzadeh M; Hemati K; Hosseinkhani S Biomed Pharmacother 2021[May]; 137 (ä): 111363 PMID33582450show ga Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of COVID-19, is reported to increase the rate of mortality worldwide. COVID-19 is associated with acute respiratory symptoms as well as blood coagulation in the vessels (thrombosis), heart attack and stroke. Given the requirement of angiotensin converting enzyme 2 (ACE2) receptor for SARS-CoV-2 entry into host cells, here we discuss how the downregulation of ACE2 in the COVID-19 patients and virus-induced shift in ACE2 catalytic equilibrium, change the concentrations of substrates such as angiotensin II, apelin-13, dynorphin-13, and products such as angiotensin (1-7), angiotensin (1-9), apelin-12, dynorphin-12 in the human body. Substrates accumulation ultimately induces inflammation, angiogenesis, thrombosis, neuronal and tissue damage while diminished products lead to the loss of the anti-inflammatory, anti-thrombotic and anti-angiogenic responses. In this review, we focus on the viral-induced imbalance between ACE2 substrates and products which exacerbates the severity of COVID-19. Considering the roadmap, we propose multiple therapeutic strategies aiming to rebalance the products of ACE2 and to ameliorate the symptoms of the disease. |*COVID-19/metabolism/physiopathology/virology[MESH] |*Paracrine Communication/drug effects/physiology[MESH] |*SARS-CoV-2/pathogenicity/physiology[MESH] |Angiotensin-Converting Enzyme 2/*metabolism[MESH] |Drug Discovery[MESH] |Humans[MESH]Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-(epmc).pdf DeepDyve Pubget Overpricing